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Disease Name 
MEDIUM CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY (MCADD) 
(ACADM DEFICIENCY; MCAD DEFICIENCY; MCADD DEFICIENCY) 
Classification:  Fatty acid oxidation defect 
Genetic Information 
Inheritance:  Autosomal recessive. 
Population 
Incidence: 
1/12,000 
 
Ethnic 
Incidence:  
Approximately 1/70 carrier rate; incidence higher in Northern Europeans and North 
American Caucasians. 
Gene & 
Location: 
ACADM, 1p31 
Common 
Mutation: 
80% carry A985G; 
T199C is 2nd most common mutation. 
OMIM #  #201450; *607008 
Disease Information 
Symptom 
Onset: 
Typically 3-24 months, variable even within family member with identical gene 
mutations and can range from neonatal to adult. MCADD may account for about three 
percent of SIDS deaths. 
Symptoms:  Episodes of hypoketotic hypoglycemia, encephalopathy, coma or SIDS triggered by a 
common illness and/or a period of fasting. In 18 percent of cases, sudden death is the 
initial presenting manifestation and up to 25 percent of patients die during their first 
episode. Survivors may have significant developmental disability, muscle weakness, 
failure to thrive and cerebral palsy. 
Physical 
Findings: 
No particular physical findings or dysmorphisms. 
Treatment:  Treatment is simple and effective: avoid fasting in patients of all ages; feeding increments 
depend on age of patient. It is imperative that glucose supplementation and hydration be 
provided during times of illness. A tangible clinical benefit of carnitine supplementation 
in patients with MCADD deficiency has not been proven, but several authors recommend 
oral supplementation with 50mg/kg/day to correct the observed secondary carnitine 
deficiency and to enhance the elimination of toxic metabolites. 
Natural 
History 
without 
treatment: 
Mortality rate of up to 25 percent when untreated. Metabolic episodes can cause 
developmental and physical delays from hypoglycemia and liver insult. 
Natural 
History 
with 
treatment: 
Most physicians familiar with MCADD presume that patients will develop normally if 
diagnosed early and treated in order to avoid hypoglycemia and liver dysfunction. 
However, this has not been proven. Death on the other hand, has not been reported once 
the diagnosis is made if treatment is carried out. Of survivors, diagnosed by clinical 
symptoms, 37 percent have neurodevelopment problems. 
Metabolic Information 
Missing 
Enzyme 
& Location: 
Medium chain acyl-CoA dehydrogenase is found in the liver, heart, muscle and 
fibroblasts. Located in mitochondria and involved in fatty acid beta-oxidation.  These 
patients are unable to metabolize C6-C10 length fatty acids. 
MS/MS 
profile: 
C6 (hexanoyl carnitine)- elevated. 
C8 (octanoyl carnitine)- elevated. 
C10 (decanoyl carnitine)- elevated. 
C10:1 (decenoyl carnitine)- elevated. C8/C10 ratio – elevated. 
Prenatal 
testing: 
Yes, DNA and enzymatic. 
Miscellaneous 
Information: 
With borderline C8 elevations, it is possible to detect carriers of MCADD. 
 
Credit:  Prepared by the North West Regional Newborn Screening Program Judith Tuerck, RN, 
MS, and Lorinda Paradise at Oregon Health Services University in Portland, Oregon 
and by Sara Copeland MD, Iowa Neonatal Metabolic Screening Program. 
Sites of 
Reference: 
National Library of Medicine Genetics Home Reference  
Medium-chain acyl-coenzyme A dehydrogenase deficiency 
http://ghr.nlm.nih.gov/condition=mediumchainacylcoenzymeadehydrogenasedeficiency 
Support 
Groups: 
United Mitochondrial Disease 
Foundation  
8085 Saltsburg Road, Suite 201  
Pittsburg, PA 15239  
412-793-8077  
412-793-6477  
info@umdf.org  
www.umdf.org  
 
FOD Family Support Group 
805 Montrose Drive 
Greensboro, NC 24710 
www.fodsupport.org/ 
Contact: Deb Lee Gould 
(336) 547-8682 
FODgroup@aol.com 
James William Lazzaro Foundation 
4493 Liberty Road 
South Euclid, OH 44121 
www.jwlsite.com/ 
Contact: Jamie Lazzaro 
(502) 254-2209 
info@jwlsite.com 
 
 
 